Literature DB >> 19300970

Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy.

Alexander Winkelmann1, Robert Patejdl, Sabine Wagner, Reiner Benecke, Uwe Klaus Zettl.   

Abstract

We discuss two cases receiving different anti-tumornecrosis-factor alpha antagonists (anti-TNF-alpha); one for psoriatic arthritis (PA) and the other for ankylosing spondylitis (AS). Due to neurological symptoms cerebral magnetic resonance imaging (MRI) was performed and cerebral lesions were detected. Our interpretations of these cerebral lesions and the resulting diagnostic and therapeutic consequences are presented in regard of data published in the medical literature.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19300970     DOI： 10.1007/s00415-008-6020-z

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  35 in total

Review 1.  Anti-tumor necrosis factor alpha-associated multiple sclerosis.

Authors:  David S Titelbaum; Alexandra Degenhardt; R Philip Kinkel
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

2.  Adalimumab-associated multiple sclerosis.

Authors:  Lamiae Bensouda-Grimaldi; Denis Mulleman; Jean-Pierre Valat; Elisabeth Autret-Leca
Journal:  J Rheumatol       Date:  2007-01       Impact factor: 4.666

Review 3.  Toward the development of rational therapies in multiple sclerosis: what is on the horizon?

Authors:  Bernhard Hemmer; Hans-Peter Hartung
Journal:  Ann Neurol       Date:  2007-10       Impact factor: 10.422

4.  Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance.

Authors:  Eric Toussirot; Edouard Pertuiset; Antoine Martin; Sylvie Melac-Ducamp; Michel Alcalay; Bruno Grardel; Paul Seror; Aleth Perdriger; Daniel Wendling; Denis Mulleman; Luc Beraneck; Xavier Mariette
Journal:  J Rheumatol       Date:  2006-03-15       Impact factor: 4.666

5.  Differentiation of multiple sclerosis plaques, subacute cerebral ischaemic infarcts, focal vasogenic oedema and lesions of subcortical arteriosclerotic encephalopathy using magnetisation transfer measurements.

Authors:  M A Reidel; C Stippich; S Heiland; B Storch-Hagenlocher; O Jansen; S Hähnel
Journal:  Neuroradiology       Date:  2003-04-17       Impact factor: 2.804

6.  Concurrence of inflammatory bowel disease and multiple sclerosis.

Authors:  K Kimura; S F Hunter; M S Thollander; E V Loftus; L J Melton; P C O'Brien; M Rodriguez; S F Phillips
Journal:  Mayo Clin Proc       Date:  2000-08       Impact factor: 7.616

Review 7.  Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumor necrosis factor.

Authors:  D A Fox
Journal:  Arch Intern Med       Date:  2000-02-28

Review 8.  Demyelination and inhibition of tumor necrosis factor (TNF).

Authors:  M D Magnano; W H Robinson; M C Genovese
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

9.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

10.  Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-alpha.

Authors:  S Yokota; T D Geppert; P E Lipsky
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422
View more
  9 in total

Review 1.  Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system.

Authors:  Sara L Montgomery; William J Bowers
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

2.  Optic Neuritis Associated or Not with TNF Antagonists in Patients with Inflammatory Bowel Disease.

Authors:  Benjamin Alexandre; Yves Vandermeeren; Olivier Dewit; Tom Moreels; Nanne de Boer; Anjan Dhar; Chris Ziady; Ariella Bar-Gil Shitrit; Flavio Steinwurz; Njegica Jojic; Giuseppe Costantino; Benoit Bihin; Jean-François Rahier; Konstantinos H Katsanos
Journal:  J Crohns Colitis       Date:  2016-01-12       Impact factor: 9.071

Review 3.  Neurological adverse events associated with anti-tumor necrosis factor α treatment.

Authors:  Antonio G Tristano
Journal:  J Neurol       Date:  2010-05-22       Impact factor: 4.849

Review 4.  Cytokine control of inflammation and repair in the pathology of multiple sclerosis.

Authors:  Jane M Rodgers; Stephen D Miller
Journal:  Yale J Biol Med       Date:  2012-12-13

5.  Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature.

Authors:  Rana Alnasser Alsukhni; Ziena Jriekh; Yasmin Aboras
Journal:  Case Rep Med       Date:  2016-10-20

Review 6.  CNS Demyelination with TNF-α Blockers.

Authors:  Elissavet Kemanetzoglou; Elisabeth Andreadou
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

7.  PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders.

Authors:  Sinah Engel; Felix Luessi; Aneka Mueller; Rudolf E Schopf; Frauke Zipp; Stefan Bittner
Journal:  Ther Adv Neurol Disord       Date:  2020-01-02       Impact factor: 6.570

8.  Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.

Authors:  E Andreadou; E Kemanetzoglou; Ch Brokalaki; M E Evangelopoulos; C Kilidireas; A Rombos; E Stamboulis
Journal:  Case Rep Neurol Med       Date:  2013-05-16

9.  Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.

Authors:  Evripidis Kaltsonoudis; Anastasia K Zikou; Paraskevi V Voulgari; Spyridon Konitsiotis; Maria I Argyropoulou; Alexandros A Drosos
Journal:  Arthritis Res Ther       Date:  2014-06-17       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.